icobrain aria

Automated detection and severity grading of ARIA-E and ARIA-H for safety monitoring of Alzheimer’s Disease therapies

Did you know?

  • icobrain aria is the only clinically validated tool for amyloid-related imaging abnormalities (ARIA) monitoring, and the only tool developed based on actual ARIA data
  • icobrain aria significantly improved radiological reader performance for ARIA-E and ARIA-H (see more details below)
  • 0865T: icobrain aria is fully reimbursed once regulatory cleared, thanks to the icometrix CPT® codes (read more)
  • icobrain aria is the first and only CADe/CADx device ever in the field of neurology!

icobrain aria for automated quantification of ARIA-E and ARIA-H

icobrain aria report

A quantitative summary report which includes a severity rating score that is seamlessly integrated into the hospital workflow.

  • ARIA-E: the number of sites of involvement of ARIA-E, their localization, and the longest axis of the largest site of involvement are measured and summarized as an ARIA-E severity score, graded according to clinical guidelines
  • ARIA-H: the number of new microhemorrhages and superficial siderosis are independently calculated and localized, and a ARIA-H severity score is reported, graded according to clinical guidelines

Why do you need computer-aided diagnosis solutions to support ARIA assessment?

The importance of ARIA safety monitoring

Safety monitoring for ARIA is a necessary part of treatment using amyloid-targeting monoclonal antibodies for treatment of Alzheimer’s Disease, as per regulatory requirements developed based on findings from clinical trials. Although findings may on some occasions be mild and asymptomatic, ARIA can be symptomatic, and is on rare occasions associated with life-threatening events. Hence, ARIA safety monitoring through regular brain Magnetic Resonance Imaging (MRI) scans will play an important role in the follow-up of patients treated with amyloid beta-directed monoclonal antibodies.

A significant increase in radiology workload

ARIA monitoring necessitates additional MRI scans per year for each patient on amyloid-targeting monoclonal antibodies. Further, reading MRI for signs of ARIA can be significantly time consuming, particularly given that for a large number of readers, the phenomena are relatively new. Even for experts, the subtlety of the radiological phenomena can prove challenging to detect. Given the large number of people who could be eligible for the new DMTs, these ARIA monitoring brain MRI requests will impact the radiology workload significantly.

The challenging task of detecting ARIA and assessing severity

ARIA (especially at the earliest stage of ‘mild’ radiological severity) can be very subtle, and involves a detailed analysis and detection/quantification of cerebral edema (ARIA-E), microhemorrhages, and superficial siderosis (ARIA-H) on brain MRI FLAIR and T2* scans.

Empower your team with icobrain aria to support the treatment of people with Alzheimer’s disease